NEW YORK, Jan. 7 (GenomeWeb News) - Perlegen Sciences and Pfizer have started a research collaboration to discover genetic markers for metabolic syndrome, Perlegen said today.
Perlegen, located in Mountain View, Calif., will use its genotyping technology to analyze thousands of patient samples for SNPs associated with metabolic syndrome. Pfizer will provide Perlegen with research funding and milestone payments and license the technology. The companies will share any therapeutic and diagnostic rights resulting from the collaboration.
Metabolic syndrome greatly increases the risk of developing cardiovascular disease and type 2 diabetes.